Clinton Group’s Integra LifeSciences IART Stock Holding History

Clinton Group’s Portfolio IART Stock Details IART Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-17,636	Closed	-$756K	–	971
2016 Q4	$756K	Buy	+17,636	New	+$717K	0.04%	456

Other funds holding IART

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Clinton Group's IART Position: Q1 2017 in Review

Clinton Group sold out of Integra LifeSciences (IART) in Q1 2017, closing a stake of 17,636 shares — an estimated $756K sold.

Clinton Group first reported a position in IART in Q4 2016 and held it in 1 quarter. The position peaked at $756K in Q4 2016. 236 funds tracked by Wall St. Rank hold IART as of Q1 2017.

Clinton Group reported no remaining Integra LifeSciences position as of Q1 2017 after selling out during the quarter.
Clinton Group sold 17,636 Integra LifeSciences shares in Q1 2017, an estimated $756K.
Clinton Group first reported a position in Integra LifeSciences in Q4 2016 and held it in 1 quarter.
Clinton Group's Integra LifeSciences position peaked at $756K in Q4 2016.
236 funds tracked by Wall St. Rank held Integra LifeSciences as of Q1 2017.

Based on Clinton Group's 13F filing for Q1 2017, filed 10 May 2017.